CareToLive RSS
Subscribe to the CareToLive RSS feed for up to date news and developments surrounding the legal battle against the FDA and more. (RSS feed reader required)
Subscribe to the CareToLive RSS feed for up to date news and developments surrounding the legal battle against the FDA and more. (RSS feed reader required)
Spread The Word
Please help spread the word about CareToLive. Any of the information found on this website can be distributed and shared freely. We only ask that you provide a link back to this website if you publish our content.
Please help spread the word about CareToLive. Any of the information found on this website can be distributed and shared freely. We only ask that you provide a link back to this website if you publish our content.
Donations
CareToLive is a not for profit corporation; however, donations are NOT tax exempt.
CareToLive is a not for profit corporation; however, donations are NOT tax exempt.
Posts Tagged ‘New York Times’
Provenge is approved!
- Provenge has been approved! Thank you to all who helped achieve this important milestone for cancer patients.
LATEST POSTS
- 02/06/2012 - Great Provenge News Released At ASCO
- 11/27/2011 - Care To Live Board Member Ted Girgus Dies of Prostate Cancer
- 09/06/2011 - Care To Live Update on SEC OIG Investigation into April 28, 2009 Dendreon Bear Raid
- 07/13/2011 - 3 Minute Video Explaining Provenge Treatment
- 06/20/2011 - Abigail Alliance Plans FDA PROTEST June 28
- 06/09/2011 - RIP Charles A. Reinwald — Cancer Cure Coalition Founder
- 04/29/2011 - Care To Live Submits Moment of Silence to CMS
- 04/28/2011 - HHS Desperately Needs Transparency Lessons From CMS
- 04/23/2011 - Please Post for Provenge!
- 04/19/2011 - Another Interim Provenge Prostate Cancer Immunotherapy CMS FOIA Response
MOST POPULAR
- Setting the Record Straight
- Provenge Is Approved But The Lies Continue
- Provenge Works & Costs the Same as Chemo & Comments by Bishop
- The Bloodshed, Bogus Threats, Birth Defects, Bashers Cover Letter
- PROVENGE WILL BE COVERED BY MEDICARE
- CareToLive sends a Freedom of Information Request to the Centers for Medicare & Medicaid Services
- ASCO Tells CMS It Should Cover Provenge
- The Centers for Medicare and Medicaid Services are requesting comments.
- Dr. Snuffy Myers Advocates For Provenge Treatment
- Senators Specter and Kerry - CMS Has Some 'Splaining To Do
WHATS GOING ON
This Is An Emergency!
We rallied outside the FDA building in Rockville, Maryland on September 18th. Now there are buses riding around Rockville and Washington, D.C., further protesting the shenanigans that took place inside the FDA building, as well as outside.
The FDA has gotten caught up with Wall Street. While it is supposed to be busy with evaluating food and drugs, its employees just can't keep their eyes off the money. So that is how decisions are being made these days.
This Is An Emergency!
We rallied outside the FDA building in Rockville, Maryland on September 18th. Now there are buses riding around Rockville and Washington, D.C., further protesting the shenanigans that took place inside the FDA building, as well as outside.
The FDA has gotten caught up with Wall Street. While it is supposed to be busy with evaluating food and drugs, its employees just can't keep their eyes off the money. So that is how decisions are being made these days.
WE'LL BE BACK
These people traveled from all across the country to protest outside the FDA Building in Rockville, Maryland. The FDA has stopped a safe and effective treatment from getting to men who need it now. The treatment is called Provenge and it treats men who have late stage prostate cancer.
The FDA appointed a panel of experts to help it decide on the safety and efficacy of Provenge. That panel voted 17-0 that Provenge was safe. And it voted 13-4 that Provenge showed substantial evidence it worked. And yet the FDA delayed it. Now it could be a year, a year and a half or it could be three years. It could be forever.
These people will keeping coming back to Rockville and they hope others will join them until the courts, the FDA, Congress or somebody does something about this travesty.
These people traveled from all across the country to protest outside the FDA Building in Rockville, Maryland. The FDA has stopped a safe and effective treatment from getting to men who need it now. The treatment is called Provenge and it treats men who have late stage prostate cancer.
The FDA appointed a panel of experts to help it decide on the safety and efficacy of Provenge. That panel voted 17-0 that Provenge was safe. And it voted 13-4 that Provenge showed substantial evidence it worked. And yet the FDA delayed it. Now it could be a year, a year and a half or it could be three years. It could be forever.
These people will keeping coming back to Rockville and they hope others will join them until the courts, the FDA, Congress or somebody does something about this travesty.
IT’S ALWAYS GOOD TO HAVE FRIENDS IN THE NEWSPAPER BUSINESS
September 16th, 2009 | Posted by Mike KearneyThe NY Times just released an article showing what a great guy Richard Pazdur is. This caused me to revisit journalistic integrity. The reason I did that is because I am going to present some rather harsh information about Richard Pazdur that this NY Times reporter, Gardiner Harris, refused to address. It appears to me that this reporter is a friend of Pazdur and this precludes him from maintaining journalistic integrity. This NY Times reporter will insult patient advocates while standing up for a guy who is supposed to be the ultimate patient advocate, a doctor.
http://www.nytimes.com/2009/09/16/health/policy/16cancer.html?_r=1
The preamble for The Society of Professional Journalists states:
Members of the Society of Professional Journalists believe that public enlightenment is the forerunner of justice and the foundation of democracy. The duty of the journalist is to further those ends by seeking truth and providing a fair and comprehensive account of events and issues. Conscientious journalists from all media and specialties strive to serve the public with thoroughness and honesty.
Please note: Conscientious journalists from all media and specialties strive to serve the public with thoroughness and honesty. It does not say to serve government employees and, in particular, doctors who work for the FDA, a government agency.
On its website, the New York Time states:
For more than a century The New York Times Company has stood for quality, integrity and distinguished journalism.
Will it remain standing for quality, integrity and distinguished journalism? The NY Times says readers dissatisfied with a response or concerned about the paper’s journalistic integrity may reach the public editor at public@nytimes.com or (212) 556-7652.
As you read the article penned in favor of Richard Pazdur, while denouncing those who protested against him, notice what is left out rather than what is puffed in. Why didn’t Gardiner mention Provenge or ImClone, two big blemishes on Richard Pazdur’s resume? Richard Pazdur is a conflicted liar. We the people should not have to see our tax dollars go to such a manipulator who pretends to be a doctor. He wouldn’t know the Hippocratic Oath if you smacked him over the head with it.
A good way to test the character of a doctor is to watch how he or she reacts in an emergency room. People are rushed to emergency room for many life threatening problems. The good doctors and nurses spring into action trying everything they can to save a life. Richard Pazdur does not react that way. In 2002, he leaked inside FDA information, which Gardiner is correct to point out is against the law, to a powerful Bristol-Myers Squibb lobbyist so he could get it into the hands of Paul Goldberg, who just happens to share tables at conferences with Richard Pazdur and this NY Times reporter, Gardiner Harris. This kept an effective treatment from reaching dying patients.
In 2007, Richard Pazdur raised his ugly head again and stopped a safe and effective, non-evasive, non-toxic prostate cancer treatment called Provenge from reaching 96,000 eligible men. The men had no other option. They had a quick destiny with death. Paul Goldberg assisted Pazdur with his non-peer reviewed medical publication called the Cancer Letter. Together, they leaked three letters that were supposed to be confidential. Why didn’t Gardiner Harris include this in his article? Continue Reading IT’S ALWAYS GOOD TO HAVE FRIENDS IN THE NEWSPAPER BUSINESS »
Popularity: 10%
Tags: Dendreon, DNDN, FDA, Howard Scher, Michael Milken, New York Times, Prostate Cancer, provenge, Richard Pazdur
Posted in The Dysfunctional FDA | 2 Comments »